Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on New Morcellator Lawsuit Filing Against Karl Storz, Inc.

Share Article

The filing of this morcellator lawsuit comes just months after the FDA warned that uterine morcellation should be avoided in the majority of women who require hysterectomy and fibroid removal surgery.

Free Case Review
This filing comes just months after U.S. health regulators warned that uterine morcellation should be avoided in most women who require hysterectomy and fibroid removal.

Power morcellator lawsuits (http://www.morcellatorlawsuit2015.com) continue to be filed in courts around the country on behalf of women who allegedly experienced the spread and upstaging of cancer due to uterine morcellation, Bernstein Liebhard LLP reports. Most recently, a Detroit woman filed suit against Karl Storz Inc., after the company’s Rotocut G1 power morcellator allegedly allowed undiagnosed cancer cells to spread beyond her uterus during a minimally invasive hysterectomy she underwent in 2011. The January 26th complaint, which is now pending in the U.S. District Court, Eastern District of Michigan, asserts that the use of the morcellator resulted in her 2014 diagnosis of advanced stage bone and breast cancer, which has required the Plaintiff to undergo extensive and intensive treatment to manage the disease. (Case No. 15-cv-10352)

“This filing comes just months after U.S. health regulators warned that uterine morcellation should be avoided in most women who require hysterectomy and fibroid removal.* It is also one of numerous claims that have been filed in recent months on behalf of women whose cancers were allegedly spread by power morcellators,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is providing free legal consultations to women who were diagnosed with advanced uterine cancers following uterine morcellation.

Power Morcellators and Cancer
Power morcellators are used to shred tissue during minimally invasive hysterectomies and fibroid removal surgeries so that it can be removed from the body via a small abdominal incision. In April 2014, the U.S. Food & Drug Administration (FDA) publically discouraged doctors from using the devices because of their potential to spread and upstage undiagnosed uterine cancer cells**. Then in November, the agency issued a second alert warning against the use of power morcellators in the majority of women who require hysterectomy and fibroid removals because of this danger. Among other things, the FDA noted that the prevalence of unsuspected uterine sarcoma in patients undergoing hysterectomy or fibroid removal surgery is 1 in 352, while the prevalence of unsuspected uterine leiomyosarcoma is 1 in 498. Both of these estimates are higher than the clinical community previously understood, the agency said.

Court records indicate that a number of other morcellator lawsuits are currently pending in U.S. courts, all of which put forth similar allegations regarding the potential for the devices to spread undiagnosed cancers. On December 23, 2014, for example, another Storz Rotocut GI morcellator claim was filed in the U.S. District Court, District of South Carolina on behalf of a woman who was diagnosed with a rare and aggressive form of uterine cancer after undergoing uterine morcellation in 2011. (Case No. 2:14-cv-04839-RMG). A similar a complaint filed on December 3, 2014, in the U.S. District Court, Western District of Missouri, alleged that the use of one of Ethicon Inc.’s Gynecare morcellators during a hysterectomy resulted in a woman’s death due to the rapid upstaging of uterine cancer. (Case 4:14-cv-01074-JTM)

Alleged victims of uterine sarcoma or other cancers allegedly spread via power morcellation may be entitled to compensation for their injury-related damages. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call 800-511-5092.

*fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm, FDA, November 24, 2014
**fda.gov/medicaldevices/safety/alertsandnotices/ucm393576.htm, FDA, April 17, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website